Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Proc Natl Acad Sci U S A ; 118(38)2021 09 21.
Article in English | MEDLINE | ID: mdl-34526398

ABSTRACT

Rheumatoid arthritis (RA) carries a twofold increased incidence of heart failure with preserved ejection fraction, accompanied by diastolic dysfunction, which can lead to death. The causes of diastolic dysfunction are unknown, and there are currently no well-characterized animal models for studying these mechanisms. Current medications for RA do not have marked beneficial cardio-protective effects. K/BxN F1 progeny and KRN control mice were analyzed over time for arthritis development, monitoring left ventricular diastolic and systolic function using echocardiography. Excised hearts were analyzed by flow cytometry, qPCR, and histology. In pharmacological experiments, K/BxN F1 mice were treated with human recombinant AnxA1 (hrAnxA1, 1 µg/mouse) or vehicle daily. K/BxN F1 mice exhibited fully developed arthritis with normal cardiac function at 4 wk; however, by week 8, all mice displayed left ventricular diastolic dysfunction with preserved ejection fraction. This dysfunction was associated with cardiac hypertrophy, myocardial inflammation and fibrosis, and inflammatory markers. Daily treatment of K/BxN F1 mice with hrAnxA1 from weeks 4 to 8 halted progression of the diastolic dysfunction. The treatment reduced cardiac transcripts of proinflammatory cytokines and profibrotic markers. At the cellular level, hrAnxA1 decreased activated T cells and increased MHC IIlow macrophage infiltration in K/BxN F1 hearts. Similar effects were obtained when hrAnxA1 was administered from week 8 to week 15. We describe an animal model of inflammatory arthritis that recapitulates the cardiomyopathy of RA. Treatment with hrAnxA1 after disease onset corrected the diastolic dysfunction through modulation of both fibroblast and inflammatory cell phenotype within the heart.


Subject(s)
Annexin A1/metabolism , Arthritis, Rheumatoid/physiopathology , Ventricular Dysfunction, Left/physiopathology , Animals , Annexin A1/pharmacology , Annexin A1/physiology , Arthritis, Rheumatoid/complications , Cardiomyopathies/pathology , Diastole , Disease Models, Animal , Heart/physiopathology , Heart Diseases/pathology , Heart Failure/pathology , Heart Failure, Diastolic/etiology , Heart Failure, Diastolic/physiopathology , Heart Ventricles/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Myocardium/pathology , Stroke Volume/drug effects , Ventricular Dysfunction, Left/etiology , Ventricular Function, Left
2.
Int J Mol Sci ; 25(9)2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38731975

ABSTRACT

Osteoarthritis (OA) is the most prevalent age-related degenerative disorder, which severely reduces the quality of life of those affected. Whilst management strategies exist, no cures are currently available. Virtually all joint resident cells generate extracellular vesicles (EVs), and alterations in chondrocyte EVs during OA have previously been reported. Herein, we investigated factors influencing chondrocyte EV release and the functional role that these EVs exhibit. Both 2D and 3D models of culturing C28I/2 chondrocytes were used for generating chondrocyte EVs. We assessed the effect of these EVs on chondrogenic gene expression as well as their uptake by chondrocytes. Collectively, the data demonstrated that chondrocyte EVs are sequestered within the cartilage ECM and that a bi-directional relationship exists between chondrocyte EV release and changes in chondrogenic differentiation. Finally, we demonstrated that the uptake of chondrocyte EVs is at least partially dependent on ß1-integrin. These results indicate that chondrocyte EVs have an autocrine homeostatic role that maintains chondrocyte phenotype. How this role is perturbed under OA conditions remains the subject of future work.


Subject(s)
Chondrocytes , Extracellular Vesicles , Homeostasis , Integrin beta1 , Chondrocytes/metabolism , Extracellular Vesicles/metabolism , Integrin beta1/metabolism , Humans , Cell Differentiation , Osteoarthritis/metabolism , Osteoarthritis/pathology , Chondrogenesis , Animals , Extracellular Matrix/metabolism , Cartilage, Articular/metabolism , Cells, Cultured
3.
FASEB J ; 36(1): e22065, 2022 01.
Article in English | MEDLINE | ID: mdl-34847625

ABSTRACT

Neutrophil trafficking is a key component of the inflammatory response. Here, we have investigated the role of the immunomodulatory lectin Galectin-9 (Gal-9) on neutrophil recruitment. Our data indicate that Gal-9 is upregulated in the inflamed vasculature of RA synovial biopsies and report the release of Gal-9 into the extracellular environment following endothelial cell activation. siRNA knockdown of endothelial Gal-9 resulted in reduced neutrophil adhesion and neutrophil recruitment was significantly reduced in Gal-9 knockout mice in a model of zymosan-induced peritonitis. We also provide evidence for Gal-9 binding sites on human neutrophils; Gal-9 binding induced neutrophil activation (increased expression of ß2 integrins and reduced expression of CD62L). Intra-vital microscopy confirmed a pro-recruitment role for Gal-9, with increased numbers of transmigrated neutrophils following Gal-9 administration. We studied the role of both soluble and immobilized Gal-9 on human neutrophil recruitment. Soluble Gal-9 significantly strengthened the interaction between neutrophils and the endothelium and inhibited neutrophil crawling on ICAM-1. When immobilized, Gal-9 functioned as an adhesion molecule and captured neutrophils from the flow. Neutrophils adherent to Gal-9 exhibited a spread/activated phenotype that was inhibited by CD18 and CD44 neutralizing antibodies, suggesting a role for these molecules in the pro-adhesive effects of Gal-9. Our data indicate that Gal-9 is expressed and released by the activated endothelium and functions both in soluble form and when immobilized as a neutrophil adhesion molecule. This study paves the way for further investigation of the role of Gal-9 in leukocyte recruitment in different inflammatory settings.


Subject(s)
CD18 Antigens/metabolism , Galectins/metabolism , Human Umbilical Vein Endothelial Cells/metabolism , Hyaluronan Receptors/metabolism , Neutrophils/metabolism , Transendothelial and Transepithelial Migration , Animals , Cell Adhesion , Humans , Mice
4.
J Immunol ; 205(10): 2840-2849, 2020 11 15.
Article in English | MEDLINE | ID: mdl-33008950

ABSTRACT

Polyunsaturated fatty acids (PUFAs) and their metabolites are potent regulators of inflammation. Generally, omega (n)-3 PUFAs are considered proresolving whereas n-6 PUFAs are classified as proinflammatory. In this study, we characterized the inflammatory response in murine peritonitis and unexpectedly found the accumulation of adrenic acid (AdA), a poorly studied n-6 PUFA. Functional studies revealed that AdA potently inhibited the formation of the chemoattractant leukotriene B4 (LTB4), specifically in human neutrophils, and this correlated with a reduction of its precursor arachidonic acid (AA) in free form. AdA exposure in human monocyte-derived macrophages enhanced efferocytosis of apoptotic human neutrophils. In vivo, AdA treatment significantly alleviated arthritis in an LTB4-dependent murine arthritis model. Our findings are, to our knowledge, the first to indicate that the n-6 fatty acid AdA effectively blocks production of LTB4 by neutrophils and could play a role in resolution of inflammation in vivo.


Subject(s)
Anti-Inflammatory Agents/metabolism , Arthritis, Experimental/immunology , Fatty Acids, Omega-6/metabolism , Fatty Acids, Unsaturated/metabolism , Peritonitis/immunology , Animals , Anti-Inflammatory Agents/analysis , Arachidonic Acid/metabolism , Arthritis, Experimental/pathology , Cells, Cultured , Fatty Acids, Omega-6/analysis , Fatty Acids, Unsaturated/analysis , Humans , Leukotriene B4/metabolism , Lipidomics , Macrophages/immunology , Macrophages/metabolism , Male , Mice , Mice, Transgenic , Neutrophils/immunology , Neutrophils/metabolism , Peritoneal Lavage , Peritonitis/pathology , Primary Cell Culture , THP-1 Cells , Zymosan/administration & dosage , Zymosan/immunology
5.
Curr Opin Clin Nutr Metab Care ; 23(2): 76-81, 2020 03.
Article in English | MEDLINE | ID: mdl-31904604

ABSTRACT

PURPOSE OF REVIEW: Sepsis is a life-threatening condition caused by a dysregulated host response to infection that remains a huge clinical challenge. Recent evidence indicates that bioactive lipid mediators derived from polyunsaturated fatty acids termed specialized pro-resolving mediators (SPMs) are promising new candidates for treating critical illness. RECENT FINDINGS: We highlight herein the protective actions of SPMs in experimental sepsis, cardiac dysfunction, and also lung and cerebral injury, and discuss their mechanisms of action. We also emphasize that failed resolution responses and dysregulated SPM pathways may provide an explanation for the ongoing chronic inflammation in many diseases including chronic heart failure. SUMMARY: Importantly, monitoring plasma SPM profiles can predict patient outcomes in sepsis indicating their utility as new early biomarkers that may help stratify patients upon ICU admission.


Subject(s)
Docosahexaenoic Acids/analogs & derivatives , Eicosanoids/pharmacology , Eicosapentaenoic Acid/analogs & derivatives , Sepsis/drug therapy , Signal Transduction/drug effects , Biomarkers/blood , Critical Illness/therapy , Docosahexaenoic Acids/blood , Eicosanoids/blood , Eicosapentaenoic Acid/blood , Humans , Sepsis/blood
6.
Semin Immunol ; 27(3): 149-60, 2015 May.
Article in English | MEDLINE | ID: mdl-25911383

ABSTRACT

The concept that chemokines, cytokines and pro-inflammatory mediators act in a co-ordinated fashion to drive the initiation of the inflammatory reaction is well understood. The significance of such networks acting during the resolution of inflammation however is poorly appreciated. In recent years, specific pro-resolving mediators were discovered which activate resolution pathways to return tissues to homeostasis. These mediators are diverse in nature, and include specialized lipid mediators (lipoxins, resolvins, protectins and maresins) proteins (annexin A1, galectins) and peptides, gaseous mediators including hydrogen sulphide, a purine (adenosine), as well as neuromodulator release under the control of the vagus nerve. Functionally, they can act to limit further leukocyte recruitment, induce neutrophil apoptosis and enhance efferocytosis by macrophages. They can also switch macrophages from classical to alternatively activated cells, promote the return of non-apoptotic cells to the lymphatics and help initiate tissue repair mechanisms and healing. Within this review we highlight the essential cellular aspects required for successful tissue resolution, briefly discuss the pro-resolution mediators that drive these processes and consider potential challenges faced by researchers in the quest to discover how inflammation resolves and why chronic inflammation persists.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Inflammation Mediators/immunology , Inflammation/drug therapy , Macrophages/immunology , Neutrophils/immunology , Apoptosis/immunology , Cell Hypoxia/immunology , Cytokines/immunology , Humans , Inflammation/immunology , Macrophage Activation/immunology
7.
J Immunol ; 197(6): 2362-8, 2016 09 15.
Article in English | MEDLINE | ID: mdl-27534559

ABSTRACT

Uncontrolled inflammation is a unifying component of many chronic inflammatory diseases, such as arthritis. Resolvins (Rvs) are a new family from the endogenous specialized proresolving mediators (SPMs) that actively stimulate resolution of inflammation. In this study, using lipid mediator metabololipidomics with murine joints we found a temporal regulation of endogenous SPMs during self-resolving inflammatory arthritis. The SPMs present in self-resolving arthritic joints include the D-series Rvs, for example, RvD1, RvD2, RvD3, and RvD4. Of note, RvD3 levels were reduced in inflamed joints from mice with delayed-resolving arthritis when compared with self-resolving inflammatory arthritis. RvD3 was also reduced in serum from rheumatoid arthritis patients compared with healthy controls. RvD3 administration reduced joint leukocytes as well as paw joint eicosanoids, clinical scores, and edema. Taken together, these findings provide evidence for dysregulated endogenous RvD3 levels in inflamed paw joints and its potent actions in reducing murine arthritis.


Subject(s)
Arthritis/immunology , Arthritis/metabolism , Fatty Acids, Unsaturated/metabolism , Gene Expression Regulation , Lipid Metabolism , Animals , Arthritis/physiopathology , Edema/prevention & control , Eicosanoids/metabolism , Fatty Acids, Unsaturated/administration & dosage , Fatty Acids, Unsaturated/blood , Humans , Joints/immunology , Joints/metabolism , Joints/physiopathology , Metabolomics , Mice
9.
Curr Opin Clin Nutr Metab Care ; 20(2): 145-152, 2017 03.
Article in English | MEDLINE | ID: mdl-28002074

ABSTRACT

PURPOSE OF REVIEW: Inflammation is a unifying component of many of the diseases that afflict Western civilizations. Nutrition therapy and, in particular, essential fatty acid supplementation is one of the approaches that is currently in use for the treatment and management of many inflammatory conditions. The purpose of the present review is to discuss the recent literature in light of the discovery that essential fatty acids are converted by the body to a novel genus of lipid mediators, termed specialized proresolving mediators (SPMs). RECENT FINDINGS: The SPM genus is composed of four mediator families - the lipoxins, resolvins, protectins, and maresins. These molecules potently and stereoselectively promote the termination of inflammation, tissue repair, and regeneration. Recent studies indicate that in disease, SPM production becomes dysregulated giving rise to a status of failed resolution. Of note, several studies found that omega-3 fatty acid supplementation, at doses within the recommended daily allowance, led to increases in several SPM families that correlate with enhanced white blood cell responses in humans and reduced inflammation in mice. SUMMARY: Given the potent biological actions of SPM in organ protection and promoting bacterial clearance, nutritional therapies enriched in omega-3 fatty acids hold promise as a potential co-therapy approach when coupled with functional lipid mediator profiling.


Subject(s)
Dietary Supplements , Fatty Acids, Omega-3/therapeutic use , Inflammation Mediators/metabolism , Inflammation/therapy , Nutrition Therapy/methods , Animals , Docosahexaenoic Acids/metabolism , Docosahexaenoic Acids/therapeutic use , Humans , Inflammation/metabolism , Lipoxins/metabolism , Lipoxins/therapeutic use , Mice
10.
Am J Pathol ; 184(8): 2333-41, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24979595

ABSTRACT

Because there is clinical evidence for an association between periodontal disease and rheumatoid arthritis, it is important to develop suitable experimental models to explore pathogenic mechanisms and therapeutic opportunities. The K/BxN serum model of inflammatory arthritis was applied using distinct protocols, and modulation of joint disruption afforded by dexamethasone and calcitonin was established in comparison to the melanocortin (MC) receptor agonist DTrp(8)-γ-melanocyte stimulating hormone (MSH; DTrp). Wild-type and MC receptor type 3 (MC3)-null mice of different ages were also used. There was significant association between severity of joint disease, induced with distinct protocols and volumes of the arthritogenic K/BxN serum, and periodontal bone damage. Therapeutic treatment with 10 µg dexamethasone, 30 ng elcatonin, and 20 µg DTrp per mouse revealed unique and distinctive pharmacological properties, with only DTrp protecting both joint and periodontal tissue. Further analyses in nonarthritic animals revealed higher susceptibility to periodontal bone loss in Mc3r(-/-) compared with wild-type mice, with significant exacerbation at 14 weeks of age. These data reveal novel protective properties of endogenous MC3 on periodontal status in health and disease and indicate that MC3 activation could lead to the development of a new genus of anti-arthritic bone-sparing therapeutics.


Subject(s)
Arthritis, Experimental/metabolism , Arthritis, Rheumatoid/metabolism , Periodontal Diseases/metabolism , Receptor, Melanocortin, Type 3/metabolism , Animals , Arthritis, Experimental/complications , Arthritis, Rheumatoid/complications , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Periodontal Diseases/complications
11.
Nature ; 461(7268): 1287-91, 2009 Oct 29.
Article in English | MEDLINE | ID: mdl-19865173

ABSTRACT

A growing body of evidence indicates that resolution of acute inflammation is an active process. Resolvins are a new family of lipid mediators enzymatically generated within resolution networks that possess unique and specific functions to orchestrate catabasis, the phase in which disease declines. Resolvin D2 (RvD2) was originally identified in resolving exudates, yet its individual contribution in resolution remained to be elucidated. Here, we establish RvD2's potent stereoselective actions in reducing excessive neutrophil trafficking to inflammatory loci. RvD2 decreased leukocyte-endothelial interactions in vivo by endothelial-dependent nitric oxide production, and by direct modulation of leukocyte adhesion receptor expression. In mice with microbial sepsis initiated by caecal ligation and puncture, RvD2 sharply decreased both local and systemic bacterial burden, excessive cytokine production and neutrophil recruitment, while increasing peritoneal mononuclear cells and macrophage phagocytosis. These multi-level pro-resolving actions of RvD2 translate to increased survival from sepsis induced by caecal ligation and puncture and surgery. Together, these results identify RvD2 as a potent endogenous regulator of excessive inflammatory responses that acts via multiple cellular targets to stimulate resolution and preserve immune vigilance.


Subject(s)
Docosahexaenoic Acids/metabolism , Leukocytes/immunology , Leukocytes/metabolism , Sepsis/immunology , Sepsis/microbiology , Animals , Docosahexaenoic Acids/chemical synthesis , Docosahexaenoic Acids/chemistry , Endothelial Cells/metabolism , Escherichia coli/growth & development , Escherichia coli/isolation & purification , Humans , Inflammation/immunology , Inflammation/metabolism , Inflammation/microbiology , Macrophages/immunology , Macrophages/microbiology , Male , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Peritoneal Cavity/cytology , Peritoneal Cavity/microbiology , Peritonitis/immunology , Peritonitis/metabolism , Peritonitis/microbiology , Phagocytosis , Reactive Oxygen Species/metabolism , Sepsis/metabolism
12.
Mol Cell Proteomics ; 12(8): 2205-19, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23660474

ABSTRACT

Altered plasma neutrophil microparticle levels have recently been implicated in a number of vascular and inflammatory diseases, yet our understanding of their actions is very limited. Herein, we investigate the proteome of neutrophil microparticles in order to shed light on their biological actions. Stimulation of human neutrophils, either in suspension or adherent to an endothelial monolayer, led to the production of microparticles containing >400 distinct proteins with only 223 being shared by the two subsets. For instance, postadherent microparticles were enriched in alpha-2 macroglobulin and ceruloplasmin, whereas microparticles produced by neutrophils in suspension were abundant in heat shock 70 kDa protein 1. Annexin A1 and lactotransferrin were expressed in both microparticle subsets. We next determined relative abundance of these proteins in three types of human microparticle samples: healthy volunteer plasma, plasma of septic patients and skin blister exudates finding that these proteins were differentially expressed on neutrophil microparticles from these samples reflecting in part the expression profiles we found in vitro. Functional assessment of the neutrophil microparticles subsets demonstrated that in response to direct stimulation neutrophil microparticles produced reactive oxygen species and leukotriene B4 as well as locomoted toward a chemotactic gradient. Finally, we investigated the actions of the two neutrophil microparticles subsets described herein on target cell responses. Microarray analysis with human primary endothelial cells incubated with either microparticle subset revealed a discrete modulation of endothelial cell gene expression profile. These findings demonstrate that neutrophil microparticles are heterogenous and can deliver packaged information propagating the activation status of the parent cell, potentially exerting novel and fundamental roles both under homeostatic and disease conditions.


Subject(s)
Cell-Derived Microparticles/metabolism , Neutrophils/physiology , Adult , Cells, Cultured , Chemotaxis, Leukocyte , Female , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Leukotriene B4/metabolism , Male , Middle Aged , Proteome , Reactive Oxygen Species/metabolism
13.
Arterioscler Thromb Vasc Biol ; 32(8): 1970-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22499990

ABSTRACT

OBJECTIVE: Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its specific receptors, the lipoxin A(4)/Annexin-A1 receptor formyl-peptide receptor 2 (FPR2/ALX) and the orphan receptor G-protein-coupled receptor 32 (GPR32) are of considerable interest. METHODS AND RESULTS: RvD1 reduced human polymorphonuclear leukocytes recruitment to endothelial cells under shear conditions as quantified using a flow chamber system. Receptor-specific antibodies blocked these anti-inflammatory actions of RvD1, with low (1 nmol/L) concentrations sensitive to GPR32 blockade, while the higher (10 nmol/L) concentration appeared FPR2/ALX-specific. Interestingly, polymorphonuclear leukocytes surface expression of FPR2/ALX but not GPR32 increased following activation with pro-inflammatory stimuli, corresponding with secretory vesicle mobilization. Lipid mediator metabololipidomics carried out with 24-hour exudates revealed that RvD1 in vivo gave a significant reduction in the levels of a number of pro-inflammatory mediators including prostaglandins and leukotriene B(4). These actions of RvD1 were abolished in fpr2 null mice. CONCLUSIONS: Pro-resolving lipid mediators and their receptors, such as RvD1 and the 2 G-protein-coupled receptors, studied here regulate resolution and may provide new therapeutic strategies for diseases with a vascular inflammatory component.


Subject(s)
Docosahexaenoic Acids/physiology , Inflammation/pathology , Neutrophils/physiology , Animals , Cell Movement , Humans , Male , Mice , Receptors, Formyl Peptide/physiology , Receptors, G-Protein-Coupled/physiology , Receptors, Lipoxin/physiology
14.
J Immunol ; 186(10): 5543-7, 2011 May 15.
Article in English | MEDLINE | ID: mdl-21460209

ABSTRACT

Endogenous microparticles (MPs) were systematically profiled during the time course of self-limited inflammation. Precursors for specialized proresolving lipid mediators were identified in MPs from inflammatory exudates using liquid chromatography tandem mass spectrometry-based metabolomics. Hence, we postulated that formation of anti-inflammatory and proresolving lipid mediators could underlie beneficial effects attributed to MPs and that this process could serve as a basis for biomimicry. Using human neutrophil-derived MPs, we constructed novel nanoparticles (NPs) containing aspirin-triggered resolvin D1 or a lipoxin A(4) analog. Enriched NPs dramatically reduced polymorphonuclear cell influx in murine peritonitis, shortened resolution intervals, and exhibited proresolving actions accelerating keratinocyte healing. The enriched NPs protected against inflammation in the temporomandibular joint. These findings indicate that humanized NPs, termed nano-proresolving medicines, are mimetics of endogenous resolving mechanisms, possess potent beneficial bioactions, can reduce nanotoxicity, and offer new therapeutic approaches.


Subject(s)
Anti-Inflammatory Agents , Docosahexaenoic Acids , Inflammation/drug therapy , Lipoxins/pharmacology , Nanoparticles/therapeutic use , Temporomandibular Joint Disorders/drug therapy , Wound Healing/drug effects , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Aspirin , Cell Movement/drug effects , Chromatography, Liquid , Docosahexaenoic Acids/metabolism , Docosahexaenoic Acids/pharmacology , Docosahexaenoic Acids/therapeutic use , Humans , Inflammation/prevention & control , Keratinocytes/drug effects , Lipids/pharmacology , Lipoxins/metabolism , Lipoxins/therapeutic use , Male , Mice , Microspheres , Molecular Mimicry , Neutrophils/immunology , Neutrophils/metabolism , Peritonitis/drug therapy , Peritonitis/immunology , Tandem Mass Spectrometry , Temporomandibular Joint/drug effects , Temporomandibular Joint/immunology , Wound Healing/immunology
15.
J Innate Immun ; 15(1): 548-561, 2023.
Article in English | MEDLINE | ID: mdl-37068475

ABSTRACT

Using a global formyl peptide receptor (Fpr) 2 knockout mouse colony, we have reported the modulatory properties of this pro-resolving receptor in polymicrobial sepsis. Herein, we have used a humanized FPR2 (hFPR2) mouse colony, bearing an intact or a selective receptor deficiency in myeloid cells to dwell on the cellular mechanisms. hFPR2 mice and myeloid cell-specific hFPR2 KO (KO) mice were subjected to cecal ligation and puncture (CLP)-induced polymicrobial sepsis. Compared with hFPR2 mice, CLP caused exacerbated cardiac dysfunction (assessed by echocardiography), worsened clinical outcome, and impaired bacterial clearance in KO mice. This pathological scenario was paralleled by increased recruitment of pro-inflammatory monocytes and reduced M2-like macrophages within the KO hearts. In peritoneal exudates of KO mice, we quantified increased neutrophil and MHC II+ macrophage numbers but decreased monocyte/macrophage and MHC II- macrophage recruitment. hFPR2 upregulation was absent in myeloid cells, and local production of lipoxin A4 was reduced in septic KO mice. Administration of the FPR2 agonist annexin A1 (AnxA1) improved cardiac function in hFPR2 septic mice but had limited beneficial effects in KO mice, in which the FPR2 ligand failed to polarize macrophages toward an MHC II- phenotype. In conclusion, FPR2 deficiency in myeloid cells exacerbates cardiac dysfunction and worsens clinical outcome in polymicrobial sepsis. The improvement of cardiac function and the host immune response by AnxA1 is more effective in hFPR2-competent septic mice.


Subject(s)
Heart Diseases , Receptors, Formyl Peptide , Sepsis , Animals , Mice , Heart Diseases/etiology , Heart Diseases/genetics , Heart Diseases/metabolism , Leukocytes , Macrophages , Mice, Inbred C57BL , Mice, Knockout , Receptors, Formyl Peptide/agonists , Receptors, Formyl Peptide/genetics , Receptors, Formyl Peptide/metabolism , Sepsis/complications
16.
Prostaglandins Other Lipid Mediat ; 98(3-4): 94-100, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22123264

ABSTRACT

The action of anti-inflammatory and anti-allergic drugs on the eicosanoid system is briefly reviewed. In addition to the aspirin-like drugs, which directly inhibit the cyclo-oxygenase enzymes, other drugs such as the glucocorticoids and the cromones also inhibit the formation of eicosanoids. In the latter cases this is bought about through the release of a protein factor that acts through formyl peptide receptors on the target cell surface. Of growing interest, is the observation that this receptor is also a target for other eicosanoids, such as lipoxins and resolvins that modulate host defence systems.


Subject(s)
Annexin A1/metabolism , Anti-Inflammatory Agents/therapeutic use , Eicosanoids/metabolism , Inflammation/drug therapy , Inflammation/metabolism , Receptors, Formyl Peptide/metabolism , Animals , Glucocorticoids/metabolism , Humans
17.
Br J Pharmacol ; 179(19): 4617-4639, 2022 10.
Article in English | MEDLINE | ID: mdl-35797341

ABSTRACT

We discuss the fascinating pharmacology of formylpeptide receptor 2 (FPR2; often referred to as FPR2/ALX since it binds lipoxin A4 ). Initially identified as a low-affinity 'relative' of FPR1, FPR2 presents complex and diverse biology. For instance, it is activated by several classes of agonists (from peptides to proteins and lipid mediators) and displays diverse expression patterns on myeloid cells as well as epithelial cells and endothelial cells, to name a few. Over the last decade, the pharmacology of FPR2 has progressed from being considered a weak chemotactic receptor to a master-regulator of the resolution of inflammation, the second phase of the acute inflammatory response. We propose that exploitation of the biology of FPR2 offers innovative ways to rectify chronic inflammatory states and represents a viable avenue to develop novel therapies. Recent elucidation of FPR2 structure will facilitate development of the anti-inflammatory and pro-resolving drugs of next decade.


Subject(s)
Lipoxins , Receptors, Lipoxin , Endothelial Cells/metabolism , Humans , Inflammation/drug therapy , Inflammation/metabolism , Lipoxins/pharmacology , Receptors, Formyl Peptide/metabolism , Receptors, Lipoxin/metabolism
18.
J Hypertens ; 40(8): 1522-1529, 2022 08 01.
Article in English | MEDLINE | ID: mdl-35730409

ABSTRACT

BACKGROUND: Rapid and accurate new biomarkers to predict risk of cardiovascular disease (CVD) are essential. The utility of extracellular vesicles in predicting the CVD risk is postulated, yet it remains unknown whether their expression is altered in response to statin therapy. METHODS: We performed in-vitro studies with human umbilical vein endothelial cells (HUVEC) and vascular smooth muscle cells (hVSMC), and conducted a nested case-control study (nCCS) in hypertensive patients ( n  = 40) randomized to either atorvastatin or placebo in the ASCOT-LLA. Cases had a major adverse cardiovascular event or death (MACE) during 3.5 years of follow-up (median) from the time of extracellular vesicle characterization while controls, matched for age and duration of treatment, remained event-free. Conditional logistic regression models determined the risk of MACE. Additionally, the relationship of extracellular vesicle levels with statin therapy was assessed. RESULTS: Added to HUVEC, extracellular vesicles increased neutrophil recruitment, and to hVSMC, aggravated calcification and proliferation. In the nCCS, compared with controls, cases (i.e. with MACE) had preceding higher levels of CD14+ and CD14+/CD41+ extracellular vesicles ( P  = 0.009 and P  = 0.012, respectively) and a significant reduction in the median size of the vesicles ( P  = 0.037). On matched analysis, higher CD14+ extracellular vesicles were associated with a 3.7-fold increased risk of MACE ( P  = 0.032). Patients treated with atorvastatin (vs. placebo) had both reduced size of extracellular vesicles and the proportion of CD146+ extracellular vesicles ( P  = 0.034 and P  = 0.020, respectively). CONCLUSION AND RELEVANCE: These pilot analyses suggest a mechanistic role for extracellular vesicles in the development of CVD, with significant and differential changes in extracellular vesicles amongst those at risk of MACE, and those on atorvastatin therapy.


Subject(s)
Cardiovascular Diseases , Extracellular Vesicles , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypertension , Atorvastatin/adverse effects , Atorvastatin/therapeutic use , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/etiology , Case-Control Studies , Endothelial Cells , Heart Disease Risk Factors , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypertension/chemically induced , Hypertension/complications , Hypertension/drug therapy , Risk Factors
19.
Cells ; 10(4)2021 04 13.
Article in English | MEDLINE | ID: mdl-33924323

ABSTRACT

Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease. The link between inflammation and atherosclerotic disease is clear; however, recent evidence suggests that inflammation may also play a role in the development of nonischemic heart disease in rheumatoid arthritis (RA) patients. We consider here the link between inflammation and cardiovascular disease in the RA community with a focus on heart failure with preserved ejection fraction. The effect of current anti-inflammatory therapeutics, used to treat RA patients, on cardiovascular disease are discussed as well as whether targeting resolution of inflammation might offer an alternative strategy for tempering inflammation and subsequent inflammation-driven comorbidities in RA.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/complications , Atherosclerosis/etiology , Heart Failure/etiology , Myocardial Infarction/etiology , Myocardial Ischemia/etiology , Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/immunology , Atherosclerosis/drug therapy , Atherosclerosis/genetics , Atherosclerosis/immunology , Etanercept/therapeutic use , Heart Failure/drug therapy , Heart Failure/genetics , Heart Failure/immunology , Humans , Hydroxychloroquine/therapeutic use , Inflammation , Methotrexate/therapeutic use , Myocardial Infarction/drug therapy , Myocardial Infarction/genetics , Myocardial Infarction/immunology , Myocardial Ischemia/drug therapy , Myocardial Ischemia/genetics , Myocardial Ischemia/immunology , Risk Factors , Stroke Volume/drug effects , Stroke Volume/physiology , Sulfasalazine/therapeutic use
20.
Free Radic Biol Med ; 175: 80-94, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34461260

ABSTRACT

Extracellular vesicles are small membrane-derived packages of information that are released from virtually all cell types. These nano-packages contain regulatory material including proteins, lipids, mRNA and microRNA and are a key mechanism of paracellular communication within a given microenvironment. Encompassed with a lipid bilayer, these organelles have been attributed numerous roles in regulating both physiological and pathological functions. Herein, we describe the role of EVs in the context of Rheumatoid and Osteoarthritis and explore how they could be harnessed to treat inflammatory and degenerative joint conditions. These structures offer a promising therapeutic strategy for treating musculoskeletal diseases due to their bioactive content, stability, small size and intrinsic ability to enter the avascular cartilage, a notoriously challenging tissue to target. We also discuss how EVs can be manipulated to load therapeutic cargo or present additional targeting moieties to enhance their beneficial actions and tissue regenerative properties.


Subject(s)
Extracellular Vesicles , MicroRNAs , Cartilage , RNA, Messenger , Wound Healing
SELECTION OF CITATIONS
SEARCH DETAIL